1	
2	
3	
4	Near point-of-care HIV viral load testing: Uptake and
5	utilization in suburban Yangon, Myanmar
6	
7	Ni Ni Tun ^{1,2*} , Frank Smithuis ^{1,2} , Nyan Lynn Tun ² , Myo Min ² , Myo Ma Ma Hlaing ¹ , Josefien
8	van Olmen ^{3*} , Lutgarde Lynen ^{4*} , Tinne Gils ⁴
9	
10	
11	
12	
13	1. HIV/TB, Medical Action Myanmar, Yangon Myanmar.
14	2. HIV/TB, Myanmar Oxford Clinical Research Unit, Yangon, Myanmar.
15	3. Spearhead research Public Health & Primary Care, University of Antwerp, Belgium.
16	4. Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
17	
18	
19	
20	
21	*Corresponding author:
22	E-mail: <u>nini@mam.org.mm (NNT)</u>
23	
24	
25	
26	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 Abstract

Introduction: HIV viral load testing in resource-limited settings is often centralized, limiting access. Near point-of-care (POC) viral load testing was introduced in Myanmar in 2017. We assessed its uptake and utilization.

Methods: Routine program data from three HIV clinics of Medical Action Myanmar were used. Annual viral load uptake was cross-sectionally analysed in people living with HIV (PLHIV) on antiretroviral therapy (ART) initiated between July 2009-June 2019. Attrition at two years was assessed between PLHIV with different access to viral load testing with Kaplan-Meier analysis. For those eligible for a first viral load when near POC viral load became available, a viral load cascade was constructed. We used logistic regression to explore predictors of confirmed virological failure after a first high viral load.

Results: Among 5271 PLHIV who started ART between July 2009-December 2019, annual 38 viral load uptake increased significantly after near POC was introduced. Attrition in the first 39 two years after ART initiation was not different among those eligible for a first viral load before 40 viral load was available, after centralized laboratory-based viral load, and after near POC viral 41 load introduction. After introduction of near POC viral load, 92% (2945/3205) of eligible 42 PLHIV received a first viral load, a median of 2.8 years (IOR: 1.4-4.4) after initiation. The 43 delay was 3.7 years (IQR: 2.8-5.1) and 0.9 years (IQR: 0.6-1.4) in those becoming eligible 44 before and after near POC viral load was available, respectively. Among those with a first viral 45 load, 95% (2796/2945) were ≤ 1000 copies/ml. Eighty-four % (125/149) of those with a viral 46 load >1000 copies/ml received enhanced adherence counselling and a follow up viral load, a 47 48 median of 119 days (IQR: 95-167) after the first viral load. Virological failure was confirmed in 67% (84/125), and 82% (69/84) of them were switched to second-line ART. Nine-three % 49 (64/69) among those switched were alive on ART at end of follow-up. Having a first viral load 50 of \geq 5000 copies/ml was associated with confirmed virological failure. 51

52 Conclusion: Near POC viral load testing enabled rapid scale-up of viral load testing in53 Myanmar. PLHIV with a high viral load were adequately managed.

54

55

56

57 Introduction

Scaling up antiretroviral therapy (ART) and access to routine HIV viral load (VL) testing are 58 critical to control the HIV epidemic [1]. The World Health Organization (WHO) recommends 59 VL to monitor people living with HIV (PLHIV) on ART, six months after the start of ART and 60 annually thereafter [2]. In case of a VL above 1000 copies/mL, enhanced adherence counselling 61 (EAC) should be performed and the VL should be repeated after three months. If the second 62 VL is also above 1000 copies/mL despite EAC, virological failure is confirmed and prompt 63 switch to a second-line regimen is indicated [3]. Though VL is regularly measured in developed 64 countries, access to VL tests is still very limited in many low resource settings and this leads to 65 delayed switching to second-line ART [4-8]. The mostly centralized VL testing demands 66 sophisticated and expensive facilities, equipment, and skilled technicians, making it difficult 67 and impractical to scale up. Moreover, challenges with blood collection, sample storage, and 68 transportation often lead to delayed results [9,10]. 69

70

To expand VL monitoring, WHO recommends point-of-care (POC) VL testing in priority 71 72 groups since 2021 [11]. In the STREAM study, the time to the return of test results and to clinical decision making following an elevated VL reduced, and retention in care improved 73 74 when POC was compared to centralized VL [12]. Near POC viral load testing, an approach 75 using testing in laboratories close to, but not inside, treatment facilities, has shown to be feasible and to enable prompt clinical action in seven countries in sub-Saharan Africa. Compared to 76 centralized testing, near POC also improved the turn-around time from sampling to results 77 delivery to PLHIV and to action when high VL was identified [13,14]. For its implementation, 78 inexpensive, low-complexity and POC assays are needed. The GeneXpert[®] HIV-1 VL assay 79 (Cepheid, Sunnyvale, CA; GeneXpert), is an in vitro diagnostic test which uses polymerase 80 chain reaction (PCR) technology to quantify HIV-1 in human plasma from PLHIV [15]. 81 Evidences have shown that the result of GeneXpert compared well with the widely used 82 Abbott[®] HIV-1 m2000 Real Time PCR (Abbott) [15–18]. The GeneXpert is suitable for near 83 84 POC VL and was included in the WHO list of prequalified in vitro diagnostics since 2017 [19]. 85

Myanmar is a low resource country with an overall estimated HIV prevalence of 0.6%, the second highest in Southeast Asia [20]. In 2019, Myanmar had an estimated 240 000 PLHIV, 10 000 new HIV infections and 7700 AIDS-related deaths. In the same year, 76% of PLHIV received ART, and 72% of them were virally suppressed. The epidemic is highly concentrated among key affected populations (KAP); HIV prevalence is 5.6% among female sex workers,

6.4% among men who have sex with men and 19% among people who inject drugs [20]. 91 Routine VL monitoring was introduced in Myanmar in 2017. Until then, VL testing remained 92 limited to centralized laboratory-based testing (Abbott Molecular; Abbott RealTime HIV-1 93 assay) situated in two major cities, Mandalay and Yangon. Hence, access to VL testing 94 remained limited. In 2017, only half of over 7000 newly initiated PLHIV in five regions across 95 the country received a VL test in the first year on ART [8]. Even in six ART clinics in Yangon, 96 a mere 58% of eligible PLHIV had received a VL test in 2019. Among the challenges 97 encountered were sample transport, resulting in long turn-around times between sampling and 98 99 reception of results [9].

100

GeneXpert for near POC VL testing was introduced in Yangon 2017 by the organization Medical Action Myanmar (MAM). Evidence on implementation of near POC VL testing remains limited [11]. In this study, we describe annual VL uptake and attrition according to access to VL over a 10-year period. For those eligible for VL after POC VL introduction, we present the VL cascade and predictors of having confirmed virological failure after a first high VL and EAC.

107

108 Methods

109 Study setting, design and population

The study took place at three MAM clinics in two of Yangon's large suburban slum areas: 110 111 Hlaingtharya (clinic 1 and 2) and Shwepyitha (clinic 3). These areas are generally inhabited by people with a low income, like day laborers, garment factory workers, taxi and highway drivers, 112 113 and female sex workers. Many people have recently been internally displaced there from rural areas. Medical Action Myanmar (MAM) is a medical organization providing care and for 114 PLHIV in Myanmar since 2009. MAM operates free-of-charge clinics which provide a package 115 of services, including primary health care such as care for non-communicable diseases, 116 reproductive healthcare, antenatal care, and tuberculosis and HIV care. Details of this HIV 117 treatment project were described previously [21]. In short, HIV clinical care was performed by 118 119 medical doctors and nurses. Counselling and adherence support through home visits were done by trained lay counsellors and outreach adherence supporters in line with the National AIDS 120 Program and WHO HIV treatment guidelines [3,21,22]. First-line treatment consisted of a 121 combination of two nucleoside/nucleotide reverse transcriptase inhibitors (zidovudine, 122 tenofovir, lamivudine, abacavir) with a non-nucleoside reverse transcriptase inhibitor 123

(efavirenz or nevirapine. Second-line regimens were composed of two nucleoside/nucleotide 124 reverse transcriptase inhibitors, ideally which had not been used in the first-line regimen and 125 one protease inhibitor (atazanavir/ritonavir or lopinavir/ritonavir). WHO recommended 2013 126 routine VL monitoring guideline was used [3]. Since 2013, one centralized Abbot HIV-1 VL 127 testing platform was available at the National Health Laboratory (NHL) in downtown Yangon 128 at 1 to 2 hours' drive from the clinics. Due to the limited capacity of the NHL, only one to two 129 samples per clinic could be sent for VL testing monthly; results could delay for over a month 130 and many samples got lost. From January 2017, the three MAM clinics shared one near POC 131 GeneXpert. The device was installed in a small laboratory within 30 minutes by motorbike from 132 each clinic and was handled by trained lay personnel. Blood samples were collected at each 133 clinic and sent daily to the laboratory. Results were provided by phone to the clinic team 134 immediately on request, and on paper the next morning. 135

- 136 We used routinely collected data of PLHIV enrolled on ART in the three MAM clinics between
- 137 July 2009 and June 2019. The database was closed in December 2019. The different analyses
- 138 with the respective study populations are shown in fig 1.

Fig 1. Study population per analysis performed in PLHIV on ART from three clinics in Yangon,
Myanmar. ART, antiretroviral treatment; EAC, enhanced adherence counselling; PLHIV, people living
with HIV/AIDS. †Group 1, six months on ART before viral load available. Group 2, eligible for viral
load when laboratory-based centralized viral load available. Group 3, eligible for viral load when near
point-of-care viral load available.

144

Annual VL uptake was analysed cross-sectionally in PLHIV eligible to have a VL done in a 145 certain year. The remaining analyses were retrospective. Attrition during the first two years on 146 ART was analysed among PLHIV who initiated ART between July 2009–June 2018. Three 147 groups for comparison were defined based on the system of VL available. Group 1 consisted 148 of PLHIV initiated on ART between July 2009–June 2012 before VL was available. Group 2 149 included PLHIV initiated on ART between July 2012-June 2016 who became eligible after 150 introduction of laboratory-based centralized VL and before near POC VL. Group 3 included 151 PLHIV initiated on ART between July 2016–June 2018, who became eligible after the 152 introduction of near POC VL. PLHIV were considered eligible for VL when they were at least 153 6 months on ART, according to routine VL monitoring guideline of WHO [3]. For the VL 154 cascade and risk factors associated with confirmed virological failure after EAC, we included 155 those initiated ART between 1 July 2009 and 30 June 2018 (minimum potential follow-up time 156

of 18 months on 31 December 2019) and who were eligible for a first VL from January 2017

158 (when POC VL was present).

159 Study variables

160 The study used routine programme data collected from standardized patient forms in hard copy, designed for the use of FUCHIA software (Follow-Up Care of Clinical HIV infection and 161 162 AIDS). Values recorded during the ART initiation visit were considered baseline for age, sex, 163 marital status, employment, KAP status, clinic, place of origin, mode of entry, WHO stage and tuberculosis co-infection. We defined CD4 at ART initiation as the measurement taken closest 164 to the date before ART initiation. Yearly uptake of viral load was defined as the proportion of 165 PLHIV on ART who had at least one VL done among those who were active on ART for at 166 least six months at the beginning of the respective year. A first VL >1000 copies/ml at least six 167 months after ART initiation was defined as first high VL. A VL of ≤1000 copies/ml is a 168 suppressed VL. A follow up VL after the first high VL and EAC of >1000 copies/ml is defined 169 as confirmed virological failure. A follow up VL of ≤ 1000 copies/ml is a re-suppressed VL. 170 EAC is a special form of counselling for ART patients with a first high VL in which the 171 172 counsellor and patient go through the identification of barriers to adherence and strategies to 173 overcome them. To construct the VL cascade, we assessed the proportion of ART patients who were eligible and who underwent VL monitoring, had a first high VL, had a follow up VL, had 174 confirmed virological failure and were switched to second-line ART [3]. Outcomes were 175 defined as follows: dead was confirmed death for any reason during the observation period. 176 177 Lost to follow up (LTFU) was defined as a delay of more than three months between an expected and actual visit. The LTFU date was the last date of the clinic visit. A patient 178 transferred to a non-MAM ART centre during the observation period was defined as transferred 179 out (TO). Those taking ART at a MAM clinic until the end of the observation period were alive 180 181 on ART. Attrition was not alive on ART due to either dead or LTFU.

182

183 Data collection and management

Date from the laboratory database and information from the EAC counselling register were compiled with clinical data in individual patient files. These clinical files in hard copy were routinely entered into the FUCHIA database by trained data clerks. After pseudonymisation, patient-level data were extracted into Microsoft Excel. In case of discrepancies between the FUCHIA database and patient files, original records were verified, and corrections made. Data cleaning and verification was done by the first author.

190

191 Data analysis

Categorical variables were summarized with frequencies and proportions whilst continuous 192 variables were summarized with medians and interguartile ranges. The trend of VL uptake 193 between was analysed with a chi-square test for trend. Kaplan-Meier techniques and a log-rank 194 test were used to compare time to attrition of ART patients who were at least six months on 195 ART before VL testing was introduced, after laboratory-based and before near POC, and after 196 197 near POC was introduced. Follow-up time was started the day PLHIV initiated ART and ended on the date of the outcome or at database closure (31 December 2019) for those alive on ART. 198 ART patients transferred out were censored the day they were transferred. We used stepwise 199 multivariable logistic regression from a saturated model to explore predictors of having a 200 confirmed virological failure after EAC. Age and sex were retained in the multivariable model, 201 as well as variables with p-values ≤ 0.05 . Odds ratios (OR) and 95% confidence intervals (CI) 202 were presented. All analyses were done using Stata 14 (Stata Corp, College Station, TX). 203

204

205 Ethics statement

As this is retrospective analysis, it would be impractical to collect informed consent. A consent waiver was obtained for the study by the Institutional Review Board of Institute of Tropical Medicine, Antwerp, Belgium (approval number IRB/AB/AC/058 1363/20) and Oxford Tropical Research Ethics Committee of University of Oxford.

210 **Results**

211 Annual viral load uptake

Between July 2009 and June 2019, 5271 PLHIV were enrolled on ART in three MAM clinics.

213 VL uptake between 2010 and 2019 was 0% (0/30), 0% (0/289), 0% (0/443), 4.6% (49/1055),

214 5.6% (89/1579), 2.4% (49/2068), 8.2% (204/2487), 32.6% (931/2858), 91.9% (2786/3033),

- 215 94.5% (2649/2804) respectively (Fig 2). There was a significant trend towards higher uptake
- 216 between 2010-2019, between 2013-2019, and between 2017-2019 (chi-square for trend p < 0.001).

218

- 219 Fig 2: Annual viral load testing uptake among eligible PLHIV in three clinics in Yangon,
- 220 Myanmar from 2010 to 2019. ART, antiretroviral treatment; PLHIV, people living with HIV/AIDS.
- 221
- 222 Comparison of attrition

223	Between July 2009-June 2018, 4291 PLHIV initiated ART. Among them, 794 (18%) PLHIV
224	were eligible to do first VL before any form of VL was introduced in Myanmar (group 1), 2386
225	(56%) were eligible after introduction of laboratory-based centralized VL and before the
226	availability of near POC VL (group 2), and 1111 (26%) became eligible after introduction of
227	near POC VL (group 3). Attrition in the first two years on ART was similar between these three
228	groups (log-rank p-value= 0.35) (Fig 3).
229	
230	Fig 3. Comparing the attrition rates on ART among three patient groups in their first two years
231	on ART. ART, antiretroviral treatment.
232	Group 1, six months on ART when no viral load available; Group 2, eligible for viral load when
233	centralized viral load available; Group 3, eligible for viral load when near point-of-care viral load
234	available
235	
236	Baseline characteristics
237	Among 4291 patients who initiated ART between July 2009 and June 2018, 3205 were eligible

for first VL testing after near POC introduction. Their characteristics at initiation are presented

in table 1. The excluded 25% (1086/4291), were those who already had a first VL done (347,

240 32%%), those LTFU (337, 31%), were those who died (228, 21%) and were TO (174, 16%)

241 before near POC introduction.

242 Table 1: Baseline characteristics of PLHIV initiated on ART and eligible for viral load after

243 near point-of care viral load introduction, Yangon, Myanmar (N=3205).

Variable		n	%
Median age,	IQR (years)	34	[28-40]
Age category	v (years)		
	<24	337	11%
	25-49	2644	82%
	>50	224	7%
Sex			
	Male	1643	51%
	Female	1562	49%
TB at initiati	TB at initiation		
	No	2202	69%
	Yes	1003	31%
Median CD4, IQR (cells/cm ³) † CD4 category (cells/cm ³) †		203	[81-332]
	<200	1579	49%
	≥200	1623	51%
WHO stage			
c	I/II	1191	37%
	III/V	2014	63%

ART history					
	Yes	126	4%		
	No	3079	96%		
Part of key p	opulation				
	No	2445	76%		
	Yes	686	21%		
	Unknown	74	2%		
Place of orig	in‡				
	Yangon	2829	88%		
	Outside Yangon	375	12%		
Marital statu	S				
	Married	2136	67%		
	Not married	1069	33%		
Employment §					
	Unemployed	847	26%		
	Employed	2356	74%		
Clinic site					
	Clinic 1	2042	64%		
	Clinic 2	537	17%		
	Clinic 3	626	20%		

†excluding three with missing data ‡excluding one with missing data

Sexcluding two with missing data

IQR, interquartile range; PLHIV, people living with HIV/AIDS; WHO, World Health Organization

246 HIV viral load cascade after near POC introduction

247 The VL cascade of those eligible for a first VL after near POC introduction is presented by

248 Fig 4.

249

250

Fig 4: Viral load cascade of PLHIV who were enrolled on ART between July 2009 and June 2018 and eligible to do first viral load after near point-of-care viral load introduction. ART, antiretroviral

treatment; EAC, enhanced adherence counselling; IQR, interquartile range; LTFU, lost to follow up;

254 PLHIV, people living with HIV/AIDS; VL, viral load.

255

Of 2945 PLHIV who had done first VL test, 945 (32%) had become eligible when near POC was available (i.e. initiated ART after July 2016). For them, the median time to a first VL was

258 0.9 years (IQR: 0.6-1.4). For 2000 (68%) PLHIV who had started ART before July 2016, the

259 median time to a first VL was 3.7 years (IQR: 2.8-5.1).

260

261 Predictors of confirmed virological failure

- 262 Predictors for confirmed virological failure after enhanced adherence counselling are shown in
- Table 2. Among 125 PLHIV who underwent EAC and had a follow-up VL, having a first high
- VL result of \geq 5000 copies/ml was significantly associated with confirmed virological failure in
- both univariate and multivariate analysis (adjusted odd ratio: 2.61 [95% CI: 1.02-6.65].

266 Table 2: Factors associated with confirmed virological failure in ART patients with

267 enhanced adherence counselling after a first high viral load in Yangon, Myanmar

			Univ	ariate analysis	Multivariate analysis			
Variable	n	%	OR	95%CI	р	aOR	95%CI	р
Age			1.00	[0.95-1.04]	0.86	1.00	[0.96-1.05]	0.91
Sex								
Male	72	58%	ref					
Female	53	42%	0.59	[0.28-1.25]	0.17	0.67	[0.31-1.47]	0.32
Tuberculosis								
No	65	52%	ref					
Yes	60	48%	2.00	[0.93-4.31]	0.08			
Tuberculosis at first VL								
No	118	94%	ref					
Yes	7	6%	3.08	[0.36-26.4]	0.31			
CD4 (cells/µL)	125	100%	1.00	[1.00-1.00]	0.50			
CD4 category (cells/µL)								
<200	92	74%	ref					
≥ 200	33	26%	0.81	[0.35-1.86]	0.61			
WHO stage								
I/II	27	22%	ref					
III/V	98	78%	1.27	[0.52-3.09]	0.60			
ART history before base	eline							
Yes	4	3%	ref					
No	121	97%	6.55	[0.66-65.0]	0.11			
Part of key population †								
No	81	65%	ref					
Yes	42	34%	0.85	[0.39-1.87]	0.69			
Place of origin								
Yangon	116	93%						
Outside Yangon	9	7%	1.77	[0.35-8.94]	0.49			
Marital status								
Married	78	62%	ref					
Not married	47	38%	1.28	[0.59-2.74]	0.53			
Employment								
Unemployed	30	24%	ref					
Employed	95	76%	1.83	[0.79-4.26]	0.16			
Clinic site								
Clinic 1	75	60%	ref					
Clinic 2	31	25%	1.54	[0.62-3.81]	0.35			
Clinic 3	19	15%	3.36	[0.90-12.56]	0.07			
Years between ART init	iation and	first VL						
<3 years	89	71%	ref					

\geq 3 years	36	29%	0.58	[0.26-1.29]	0.18			
First viral load								
<5000 copies/ml	25	20%	ref					
≥5000 copies/ml	100	80%	2.79	[1.14-6.84]	0.03	2.61	[1.02-6.65]	0.05

† excluding two with missing data

Variables reported those measured at ART initiation, unless specified

aOR, adjusted odds ratio; ART, antiretroviral treatment; OR, odds ratio; viral load, VL; WHO, World Health Organization

268

269 **Discussion**

This study is the first assessment of VL testing uptake and management after introduction of near POC VL in Myanmar. When near POC VL was introduced, VL uptake improved significantly, but two-year attrition was similar when comparing groups with different access to VL. Despite long delays until a first VL was done, only 5% of PLHIV had a first unsuppressed VL, and their subsequent VL cascade was adequately managed. Having a first high viral load of 5000 copies/ml or higher was associated with confirmed virological failure.

Viral load uptake increased significantly after introduction of near-POC VL as compared to 276 277 laboratory-based VL. While centralized, laboratory-based VL had been introduced in 2013, VL uptake remained below 10% of those eligible until 2016. This was due in part to the fact that 278 the two central laboratories accepted only a small number of tests and it took up to a month to 279 280 get the test results. After 2017, there was a rapid scale up of VL testing, reaching 95% of those eligible in 2019. Contributing to this fast increase were the test result delivery time, which 281 reduced from about a month to one day. This probably increased the motivation of the doctors 282 to perform VL testing and for PLHIV have a VL test done. The relatively simple viral load 283 procedure on GeneXpert allowed task shifting to lay workers. We were also able to secure 284 uninterrupted supply of cartridges, which had been a challenge at introduction of centralised 285 VL in Yangon. A reduction of results notification time was also observed after introduction of 286 near POC VL in seven countries in sub-Saharan Africa [14]. 287

288

We found no difference in attrition in the first two years after ART initiation between three groups of PLHIV with different access to VL testing (no access, limited access to centralized testing or access to near POC testing). In the STREAM randomised controlled trial, retention in care and viral suppression was significantly better in a group receiving POC VL group with tasking shifting compared to laboratory-based VL. However, retention at any clinic 12 months after ART initiation was also not found to be different between the groups [12]. In Uganda, access to viral load also did not improve survival when participants were randomized to

different VL monitoring strategies [23]. We did not correct for confounders in our analysis of
attrition and might thus not accurately capture the impact of near POC VL. The follow up period
of two years may also be short to witness an effect of improved access to VL testing in a reallife setting. In addition, retention in care was already high before VL introduction in our cohort
and remained high when laboratory-based VL was available. Measures to improve medicine
adherence and retention in care should thus be continued and strengthened, regardless of the
VL platform used.

303

304 The VL cascade was managed adequately after POC VL was made available. Ninety-two % of 305 PLHIV eligible for a first VL had a VL done. This is high when compared to review data from 306 low-and middle income countries, in which the median VL testing coverage was 74% (IQR: 46-82%) [24]. The time to a first VL was very long, but reduced when near POC became 307 308 available from almost four to about one year. Despite the long waiting time for a first VL, 95% of patients who had a first VL done had a VL below1000 copies/ml. This is also high compared 309 310 to other reports in resource-limited settings in Africa and Asia, including Myanmar, in which suppression rates were found between 72 and 91% [4,9,25–29]. As treatment adherence was 311 312 probably good in our cohort, the long delay in VL testing did not have a large negative impact on viral load results. In earlier studies in Myanmar, high retention was also reported [21,30]. 313

314

Of the PLHIV with a first high VL result, 85% received a follow up VL test after EAC. A recent 315 review by Pham et al. reported that only 66% (median, IQR: 38-77%) of those eligible had a 316 follow-up VL in low-and middle-income settings [24]. Only 41 (33%) of the patients had their 317 VL re-suppressed after EAC in our study. In comparison, a systematic review from 2019 318 showed a higher re-suppression rate (53%) after EAC [31]. In our study, the high initial VL 319 was probably based on true resistance and hence, patients would not benefit from EAC. Of the 320 84 patients whose virological failure was confirmed, 69 (82%) were switched to second line 321 ART. This is again much higher when compared to Pham et al., reporting a switch rate of 45% 322 323 (mean, IQR: 35-71) [24]. The highest switch rate came from a study from Myanmar, in which 85% of patients switched to second-line ART [8]. Like in our study, this was a cohort supported 324 325 by a medical organization, in which patient follow-up might benefit from more resources compared to other settings. 326

327

We also looked at the factors associated with confirmed virological failure among the patients with a first high VL. In the 125 patients with a follow-up VL, a first high VL result of \geq 5000

copies/ml was significantly associated with confirmed virological failure (adjusted odds ratio 2.61, 95%CI:1.02-6.65). Similar findings were found in Zimbabwe and Ethiopia where PLHIV with a first VL of respectively \geq 5000 copies/ml and \geq 10,000 copies/mL also had higher odds of virological failure after EAC. In PLHIV cohorts with high levels of adherence, high initial VL due to underlying resistance might indeed predict virological failure [29,32].

335

This study has several limitations. Since it is a retrospective analysis, there could be important 336 unmeasured confounding factors. In addition, the sample size of the regression analysis was 337 small, allowing for limited conclusions based on the results. Our clinics are managed by 338 Medical Action Myanmar, a private medical organization receiving external funding, and 339 340 results might not be generalizable to other facilities. However, all near POC sampling and analysis were managed by trained lay workers, with skills easily transferable to public health 341 342 facilities. Our study also has important strengths. This study is the first one to document the impact of near POC VL on VL uptake in Myanmar, and in Southeast Asia. We present real-life 343 344 results from ten years of programme implementation in a large cohort in a resource-limited setting. The principal investigator verified source files to correct incomplete data and errors that 345 346 were detected in the database. In this way, despite the retrospective design, we had very little missing data. 347

348

We respond to a research gap identified by WHO addressing implementation of POC VL. The 349 WHO conditionally recommends POC viral load, adapted to the capacity of health facilities, 350 and while giving priority to populations at risk [11]. We provided near POC VL for all PLHIV 351 eligible for viral load. After 2019, access to services for PLHIV deteriorated rapidly in 352 Myanmar due to COVID-19 further due to political turmoil [33,34]. In such situations, 353 providing services faster and closer to patients could partly mitigate impact of service 354 disruption. Future research should show if near point-of-care viral load has this potential. In 355 other contexts, with similar constraints in access and resources, near POC could provide an 356 357 acceptable alternative to POC testing, improving time to a VL and subsequent management while limiting the burden on primary care facilities. 358

359

360 **Conclusion**

Near POC testing rapidly increased VL uptake and lead to adequate management of ART patients with a first high VL result. In resource-constraint settings, near POC VL implementation should be considered as a priority measure to control the HIV epidemic.

- 364
- 365

366

367 Competing interests

368 There are no conflicts of interests for all authors.

369

370 Authors' contributions

NNT conceived the conceived the idea and designed the study. LL, JVO & TG supported study design. FS supervised data acquisition. NNT, MM, MMMH and NLT performed data acquisition and analysis. NNT, FS, LL, JVO and TG performed data interpretation. TG supported statistical analysis. NNT drafted the first version of the manuscript, which was subsequently critically revised, edited and approved by all authors.

376

377 Acknowledgments

We would like to thank the contribution of the study participants, and the medical and data
teams from Medical Action Myanmar, and the Myanmar Oxford Clinical Research Unit,
Yangon, Myanmar.

381

382

383 **References**

- 384
- Joint United Nations Programme on HIV/AIDS (UNAIDS). Understanding Fast-Track.
 Accelerating action to end the AIDS epidemic by 2030 [Internet]. Geneva, Switserland:
 UNAIDS; 2015 [cited 2022 May 24]. Available from:
- https://www.unaids.org/sites/default/files/media_asset/201506_JC2743_Understanding
 FastTrack_en.pdf
- 390 2. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs

for treating and preventing HIV infection: recommendations for a public health 391 approach [Internet]. Geneva, Switserland: WHO; 2013 [cited 2022 May 24]. Available 392 from: 393 https://apps.who.int/iris/bitstream/handle/10665/85321/9789241505727 eng.pdf?seque 394 nce=1 395 3. World Health Organization. Consolidated Guidelines on the use of antiretroviral drugs 396 for treating and preventing HIV infection [Internet]. Geneva, Switserland: WHO; 2016 397 [cited 2022 May 24]. Available from: 398 https://apps.who.int/iris/bitstream/handle/10665/208825/97892?sequence=1 399 Mesic A, Spina A, Mar HT, Thit P, Decroo T, Lenglet A, et al. Predictors of virological 400 4. failure among people living with HIV receiving first line antiretroviral treatment in 401 Myanmar: retrospective cohort analysis. AIDS Res. Ther. 2021;18(1):16 402 5. Ssempijja V, Nakigozi G, Chang L, Gray R, Wawer M, Ndyanabo A, et al. Rates of 403 404 switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with 405 406 virologic failure in Rakai, Uganda. BMC Infect Dis. 2017;17:1-10. 6. Petersen ML, Tran L, Geng EH, Reynolds SJ, Kambugu A, Wood R, et al. Delayed 407 switch of antiretroviral therapy after virologic failure associated with elevated mortality 408 among HIV-infected adults in Africa. AIDS. 2014;28(14):2097-107 409 410 7. Awungafac G, Amin ET, Fualefac A, Takah NF, Agyingi LA, Nwobegahay J et al. Viral load testing and the use of test results for clinical decision making for HIV 411 treatment in Cameroon : An insight into the clinic- laboratory interface. PLoS One. 412 413 2018;13(6):e0198686 Thu Ya SS, Harries AD, Wai KT, Kyaw NTT, Aung TK MJ et al. Performance and 414 8. Outcomes of Routine Viral Load Testing in People Living with HIV Newly Initiating 415 ART in the Integrated HIV Care Program in Myanmar between January 2016 and 416 December 2017. Trop Med Infect Dis.2020;5(3):140 417 418 9. Thinn KK, Thekkur P, Kyaw NTT, Aye NS, Zaw TM, Soan P, et al. Uptake of routine viral load testing among people living with HIV and its implementation challenges in 419 420 Yangon region of Myanmar: A mixed-methods study. BMJ Open.2019; 9(12): e032678 Roberts T, Cohn J, Bonner K, Hargreaves S. Scale-up of Routine Viral Load Testing in 10. 421

Resource-Poor Settings: Current and Future Implementation Challenges. Clin Infect 422 Dis. 2016; 62(8):1043-48. 423 World Health Organization. Consolidated guidelines on HIV prevention, testing, 424 11. treatment, service delivery and monitoring: recommendations for a public health 425 426 approach [Internet]. Geneva, Switserland: WHO; 2021 [cited 2022 May 24]. Available at: https://www.who.int/publications/i/item/9789240031593 427 12. Drain PK, Dorward J, Violette LR, Quame-Amaglo J, Thomas KK, Samsunder N, et al. 428 Point-of-care HIV viral load testing combined with task shifting to improve treatment 429 outcomes (STREAM): findings from an open-label, non-inferiority, randomised 430 controlled trial. Lancet HIV. 2020 Apr;7(4):e229-e237. 431 13. Ganesh P, Heller T, Chione B, Gumulira J, Gugsa S, Khan S, et al. Near point-of-care 432 HIV viral load: Targeted testing at large facilities. J Acquir Immune Defic Syndr. 2021 433 Feb 1;86(2):258-263. 434 435 14. Boeke CE, Joseph J, Atem C, Banda C, Coulibaly KD, Doi N, et al. Evaluation of near point-of-care viral load implementation in public health facilities across seven 436 countries in sub-Saharan Africa. J Int AIDS Soc. 2021;24(1). 437 Nash M, Huddart S, Badar S, Baliga S, Saravu K, Paia M. Performance of the xpert 438 15. HIV-1 viral load assay: A systematic review and meta-analysis. J Clin Microbiol. 2018; 439 440 26;56(4):e01673-17. Kulkarni S, Jadhav S, Khopkar P, Sane S, Londhe R, Chimanpure V, et al. GeneXpert 441 16. 442 HIV-1 quant assay, a new tool for scale up of viral load monitoring in the success of ART programme in India. BMC Infect Dis. 2017; 17(1):506 443 17. Movo S, Mohammed T, Wirth KE, Prague M, Bennett K, Holme MP, et al. Point-of-444 care Cepheid Xpert HIV-1 viral load test in rural African communities is feasible and 445 reliable. J Clin Microbiol. 2016 Dec;54(12):3050-3055 446 447 18. Manavi K, Hodson J, Masuka S, Singo M, Dedicoat K, Osman H. Correlation between Cepheid GeneXpert and Abbott M2000 assays for HIV viral load measurements. Int J 448 STD AIDS. 2021; 32(5):444-448. 449 19. World Health Organization. Prequalification of Medical Products. WHO Public 450 451 Reports for In Vitro Diagnostics [Internet]. Geneva, Switserland: WHO; 2019 [cited

452		2022 May 24]. Available from: https://extranet.who.int/pqweb/vitro-
453		diagnostics/prequalification-reports/whopr
454 455 456	20.	Joint United Nations Programme on HIV/AIDS. UNAIDS data 2020 [Internet]. Geneva, Switserland: UNAIDS; 2020 [cited 2022 May 24]. Available from:. https://www.unaids.org/en/resources/documents/2020/unaids-data
457 458 459	21.	Tun NN, McLean ARD, Wilkins E, Hlaing MMM, Aung YY, Linn T, et al. Integration of HIV services with primary care in Yangon, Myanmar: a retrospective cohort analysis. HIV Med. 2020;21: 547–556.
460 461 462 463 464	22.	National AIDS program, Ministry of Health Myanmar. Guidelines for the clinical Management Of HIV infection in Adults and Adolescents in Myanmar [Internet]. Yangon, Myanmar: Ministry of Health; 2011 [cited 2022 May 24]. Available from: https://reliefweb.int/report/myanmar/guidelines-clinical-management-hiv-infection- adults-and-adolescents-myanmar
465 466 467	23.	Mermin J, Ekwaru JP, Were W, Degerman R, Bunnell R, Kaharuza F et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: Randomised trial. BMJ. 2011;343:d6792
468 469 470 471	24.	Pham MD, Nguyen HV, Anderson D, Crowe S, Luchters S. Viral Load Monitoring for People Living with HIV in the Era of Test and Treat : Progress Made and Challenges Ahead – A Systematic Review [Internet]. 2021; Preprint (Version 1) [cited 2022 May 24]. Available from: https://www.researchsquare.com/article/rs-1091142/v1
472 473 474	25.	Ferradini L, Laureillard D, Prak N, Ngeth C, Fernandez M, Pinoges L, et al. Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. AIDS 2007;21: 2293–2301.
475 476 477	26.	Ma Y, Zhao D, Yu L, Bulterys M, Matthew, Zhao Y, et al. Predictors of Virologic Failure in HIV-1–Infected Adults Receiving First-Line Antiretroviral Therapy in 8 Provinces in China. Clin Inf Dis 2010;50(2):264–71
478 479 480	27.	Kiweewa F, Esber A, Musingye E, Reed D, Crowell TA, Cham F, et al. HIV virologic failure and its predictors among HIV-infected adults on antiretroviral therapy in the African Cohort Study. PLoS One. 2019;14(2):e0211344.
481	28.	Assemie MA, Alene M, Ketema DB, Mulatu S. Treatment failure and associated

482 483		factors among first line patients on highly active antiretroviral therapy in Ethiopia: a systematic review and meta-analysis. Glob Heal Res Policy. 2019;4 (32).
484 485 486 487	29.	Bvochora T, Satyanarayana S, Takarinda K.C, Bara H, Chonzi P, Komtenza B et al. Enhanced adherence counselling and viral load suppression in HIV seropositive patients with an initial high viral load in Harare, Zimbabwe: Operational issues. PLoS One. 2019;14(2):e0211326.
488 489 490 491	30.	Sabapathy K, Ford N, Chan KN, Kyaw MK, Elema R, Smithuis F, et al. Treatment outcomes from the largest antiretroviral treatment program in Myanmar (Burma): A cohort analysis of retention after scale-up. J Acquir Immune Defic Syndr. 2012; ;60(2):e53-62
492 493 494	31.	Ford N, Orrell C, Shubber Z, Apollo T, Vojnov L. HIV viral resuppression following an elevated viral load: a systematic review and meta-analysis. J Int AIDS Soc. 2019;22(11):e25415.
495 496 497 498	32.	Bisetegn G, Arefaynie M, Mohammed A, Fentaw Z, Muche A, Dewau R, et al. Predictors of virological failure after adherence-enhancement counseling among first- line adults living with HIV/AIDS in Kombolcha town, northeast Ethiopia. HIV/AIDS - Res Palliat Care. 2021;13: 91–97.
499 500 501 502	33.	Oo HN, Myo N, Wan A, Soan P, Tawil O, Lwin MK, et al. How Myanmar Is Working to Maintain Essential Services for People Living With HIV and Key Populations During the Covid-19 Pandemic. J Int Assoc Provid AIDS Care. 2021;20:23259582211017742.
503 504 505	34.	Aung MN, Shiu C, Chen W. Amid political and civil unrest in Myanmar , health services are inaccessible. Lancet. 2021 Apr 17;397(10283):1446.
506		
508		
509		
510		







